La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Magle Chemoswed Holding Bilan de santé

Santé financière contrôle des critères 4/6

Magle Chemoswed Holding possède un total de capitaux propres de SEK160.3M et une dette totale de SEK55.8M, ce qui porte son ratio d'endettement à 34.8%. Son actif total et son passif total sont SEK304.3M et de SEK144.0M. L'EBIT de Magle Chemoswed Holding est SEK13.3M ce qui fait que son ratio de couverture des intérêts 3.5. Elle dispose de liquidités et de placements à court terme de SEK3.9M.

Informations clés

34.8%

Ratio d'endettement

SEK 55.81m

Dette

Ratio de couverture des intérêts	3.5x
Argent liquide	SEK 3.93m
Fonds propres	SEK 160.31m
Total du passif	SEK 143.98m
Total des actifs	SEK 304.29m

Mises à jour récentes de la santé financière

Magle Chemoswed Holding (STO:MAGLE) Has A Pretty Healthy Balance Sheet

Jun 19

Recent updates

Market Participants Recognise Magle Chemoswed Holding AB (publ)'s (STO:MAGLE) Earnings Pushing Shares 37% Higher

Jun 26

Magle Chemoswed Holding (STO:MAGLE) Has A Pretty Healthy Balance Sheet

Jun 19

Magle Chemoswed Holding's (STO:MAGLE) Earnings Are Of Questionable Quality

Apr 26

Earnings Tell The Story For Magle Chemoswed Holding AB (publ) (STO:MAGLE) As Its Stock Soars 28%

Mar 29

Magle Chemoswed Holding AB (publ)'s (STO:MAGLE) Price In Tune With Earnings

Oct 05

Should You Be Impressed By Magle Chemoswed Holding AB (publ)'s (STO:MAGLE) ROE?

Jan 22

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de MAGLE ( SEK95.9M ) dépassent ses passifs à court terme ( SEK87.3M ).

Passif à long terme: Les actifs à court terme de MAGLE ( SEK95.9M ) dépassent ses passifs à long terme ( SEK56.7M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: Le ratio dette nette/capitaux propres de MAGLE ( 32.4% ) est considéré comme satisfaisant.

Réduire la dette: Le ratio d'endettement de MAGLE est passé de 12.8% à 34.8% au cours des 5 dernières années.

Couverture de la dette: La dette de MAGLE n'est pas bien couverte par le flux de trésorerie opérationnel ( 13% ).

Couverture des intérêts: Les paiements d'intérêts de MAGLE sur sa dette sont bien couverts par l'EBIT ( 3.5 x couverture).

Magle Chemoswed Holding Bilan de santé

Santé financière contrôle des critères 4/6

Informations clés

Mises à jour récentes de la santé financière

Magle Chemoswed Holding (STO:MAGLE) Has A Pretty Healthy Balance Sheet

Recent updates

New minor risk - Share price stability

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment improves as stock rises 16%

Market Participants Recognise Magle Chemoswed Holding AB (publ)'s (STO:MAGLE) Earnings Pushing Shares 37% Higher

Magle Chemoswed Holding (STO:MAGLE) Has A Pretty Healthy Balance Sheet

Magle Chemoswed Holding's (STO:MAGLE) Earnings Are Of Questionable Quality

First quarter 2024 earnings released: EPS: kr0.27 (vs kr0.27 in 1Q 2023)

Earnings Tell The Story For Magle Chemoswed Holding AB (publ) (STO:MAGLE) As Its Stock Soars 28%

Magle Chemoswed Holding AB (publ) (OM:MAGLE) made a tender to acquire 99.96% stake in Amniotics AB (publ) (OM:AMNI) from LSCS Invest AB, Deflexum AB, Marcus Larsson and other for SEK 10.9 million.

Full year 2023 earnings: EPS and revenues exceed analyst expectations

New minor risk - Financial data availability

Magle Chemoswed Holding AB (publ) to Report Q4, 2024 Results on Feb 26, 2025

No independent directors

New minor risk - Share price stability

Magle Chemoswed Holding AB (publ)'s (STO:MAGLE) Price In Tune With Earnings

Investor sentiment improves as stock rises 16%

Full year 2022 earnings released: EPS: kr0.87 (vs kr0.39 in FY 2021)

Magle Chemoswed Holding AB 's Proprietary Product Axxo® Woundgel Receives Regulatory Approval in Kuwait

Magle Group's Vascular Embolic Product Embocept® S Receives Regulatory Approval in Argentina

No independent directors

Magle Group Appoints New Chief Marketing and Innovation Officer

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Magle Chemoswed Holding AB Announces the Resignation of Julia Kamber Rouhi from the Board of Directors of Magle Chemoswed Holding

Magle Group Announces First Patients Enrolled in a Post-Market Study of Medical Device SmartPAN®

Magle Chemoswed Holding AB (publ) Announces Post Market Clinical Study for SmartPAN®

Magle Chemoswed Holding AB (publ) to Report Q4, 2022 Results on Feb 16, 2023

Investor sentiment deteriorated over the past week

No independent directors

Full year 2021 earnings released: EPS: kr0.39 (vs kr0.24 in FY 2020)

Magle Chemoswed Holding AB (publ), Annual General Meeting, May 17, 2022

Investor sentiment improved over the past week

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Magle Chemoswed Holding AB (publ) to Report Fiscal Year 2021 Results on Feb 25, 2022

Full year 2020 earnings released: EPS kr0.24

Should You Be Impressed By Magle Chemoswed Holding AB (publ)'s (STO:MAGLE) ROE?

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

New 90-day high: kr44.60

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Magle Chemoswed Holding AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 20 million.

New 90-day high: kr35.00

New 90-day high: kr34.60

Magle Chemoswed Holding AB (publ) to Report Fiscal Year 2020 Results on Apr 14, 2021

New 90-day high: kr33.50

New 90-day high: kr30.90

Magle Chemoswed Holding AB (Publ) Announces the Appointment of Joel Eklund as New Member of the Board

Magle Chemoswed Holding AB (publ) has completed an IPO in the amount of SEK 50 million.

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Découvrir des entreprises saines